Davis Mellar P
The Harry R Horvitz Center for Palliative Medicine, Cleveland Clinic Foundation, M76, Cleveland, OH 44195, USA.
Support Care Cancer. 2007 Feb;15(2):221-4. doi: 10.1007/s00520-006-0111-0. Epub 2006 Nov 28.
Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters.
Trazodone is well-absorbed by the mouth and is metabolized by three cytochromes: CYP1A2, CYP2D6, and CYP3A4. Clinical benefits include reduced insomnia in those depressed and/or on antidepressants. Pain may be relieved by mechanisms similar to venlafaxine. Delirium unresponsive to neuroleptics has been reported to respond to trazodone. Drug interactions are a risk due to cytochrome metabolism.
Trazodone has a unique pharmacology, which may be an advantage in palliating symptoms; however, little evidence is available through cohort or randomized trials to give guidance to its use.
曲唑酮是一种独特的抗抑郁药,它可阻断突触后5-羟色胺(5-HT)受体5-HT(2A)和5-HT(2C),并微弱抑制突触前5-HT转运体。
曲唑酮口服吸收良好,由三种细胞色素代谢:CYP1A2、CYP2D6和CYP3A4。临床益处包括减轻抑郁症患者和/或服用抗抑郁药患者的失眠症状。其缓解疼痛的机制可能与文拉法辛相似。据报道,对神经安定药无反应的谵妄对曲唑酮有反应。由于细胞色素代谢,存在药物相互作用的风险。
曲唑酮具有独特的药理学特性,这在缓解症状方面可能是一个优势;然而,队列研究或随机试验几乎没有证据可为其使用提供指导。